Eli Lilly (LLY)

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The past week saw market turbulence, with President Trump's new gold tariffs, Eli Lilly's dramatic stock drop, a weakening jobs report fueling recession fears, and a divided Federal Reserve debating rate cuts.

It looked good next to a company that has been stealing its thunder lately.

Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of strong corporate earnings, sustained momentum in the technology sector, and a perceived easing of anxieties related

The drugmaker is in a 35% drawdown.

After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat.

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

SoundHound stock rallied Friday after the conversational AI technology company posted a huge gain in revenue.

The drugmaker continues to grab headlines for all the right reasons.

Eli Lilly has normally been a market-beating stock, but not this year.

Apple's $704B in buybacks over 10 years exceeds the market cap of 488 S&P 500 firms. Learn why it still avoids major acquisitions.

U.S. stock futures rose on Friday after ending on a mixed note on Thursday. Futures of major benchmark indices were higher.

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

CNN's Fear & Greed Index declined but remained in Neutral zone on Thursday. Dow fell 200 points, while Apple, Eli Lilly reported earnings.

Wall Street ended Thursday on a shaky note as disappointing drug trial results, new trade tariffs, and cautious corporate guidance weighed on sentiment. While Apple (AAPL | +3.2%) basked in the glow of domestic investment optimism, heavyweights like Eli Lilly (LLY | -14.1%) and Airbnb (ABNB | -8.0%) dragged major indexes in opposite directions.

The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70

Eli Lilly's late-stage data for weight-loss pill falls short of expectations.

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98 billion to $100 billion from its market capitalization. The significant sell-off was triggered by the release of disappointing clinical trial data

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase. 

Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling.